Eledon Pharmaceuticals to Present at the Jefferies Healthcare Conference

Rhea-AI Summary

Eledon Pharmaceuticals, a clinical stage biopharmaceutical company focused on innovative treatments for organ transplantation and autoimmune diseases, announced that CEO David-Alexandre C. Gros will present at the Jefferies Healthcare Conference on June 9, 2022, at 3:30 p.m. ET in New York City. Interested parties can register for the webcast in advance. Eledon is developing tegoprubart, an anti-CD40L antibody targeting CD40 Ligand, aimed at improving outcomes for patients in need of transplants and those suffering from neurodegenerative diseases.

IRVINE, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Eledon Pharmaceuticals, Inc. (“Eledon”) (NASDAQ: ELDN), a patient-focused clinical stage biopharmaceutical company committed to the development of innovative and impactful treatments for organ and cell transplantation, autoimmune conditions, and neurodegenerative disease, today announced that David-Alexandre C. Gros, Chief Executive Officer, will present a company overview at the Jefferies Healthcare Conference on Thursday, June 9, 2022 at 3:30 p.m. ET. The conference will be taking place June 8-10, 2022 in New York City.

To register in advance for the presentation webcast, sign up here.

A webcast replay will be accessible following the live session on the Events page of the Investors section on the Company’s website at https://ir.eledon.com/events-and-presentations/events.

About Eledon Pharmaceuticals and tegoprubart (formerly AT-1501)

Eledon Pharmaceuticals is a clinical stage biotechnology company using its expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop potential treatments for persons requiring an organ or cell-based transplant, living with autoimmune disease, or living with ALS. The company’s lead compound in development is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a well-validated biological target with broad therapeutic potential. Eledon is headquartered in Irvine, Calif. For more information, please visit the company’s website at www.eledon.com.

Follow Eledon Pharmaceuticals on social media: LinkedIn; Twitter

Investor Contact:

Stephen Jasper
Gilmartin Group
(858) 525-2047
stephen@gilmartinir.com

FAQ

What is the date and time of Eledon Pharmaceuticals' presentation at the Jefferies Healthcare Conference?

Eledon Pharmaceuticals will present on June 9, 2022, at 3:30 p.m. ET.

Where will the Jefferies Healthcare Conference take place?

The conference will take place in New York City from June 8-10, 2022.

How can I register for Eledon Pharmaceuticals' presentation webcast?

You can register for the presentation webcast in advance through the link provided in the press release.

What is tegoprubart and its significance in Eledon's research?

Tegoprubart is Eledon's lead compound, an anti-CD40L antibody targeting CD40 Ligand, with potential for treating organ transplant patients and those with autoimmune diseases.

Who is presenting on behalf of Eledon Pharmaceuticals at the conference?

David-Alexandre C. Gros, the Chief Executive Officer, will present on behalf of Eledon Pharmaceuticals.